Oil Prices Rise as Houthi Strikes on Riyadh Fuel Middle East Tensions 
Petrobras Joins Brazil’s New Diesel Subsidy Program 
Westinghouse Targets $50 Billion Valuation in U.S. IPO 
Bessent, He Lifeng to Discuss AI Security and Trade in New York 
Asia Stocks Rise on AI Demand as Oil Eases 
Paramount Skydance Faces $30 Million Film Penalty in Warner Bros. Deal 
Telix to Acquire Germany’s ITM in $1.65 Billion Radiopharma Deal 
Japan, U.S. Discuss $19 Billion GlobalFoundries Chip Plant 
US Northeast Airports Resume Operations After Telecom Outage Disrupts Thousands of Flights 
FAA Allows Boeing to Sell 35 More 777F Freighters Beyond 2028 
Gold Prices Slip as Strong Dollar and Hawkish Fed Pressure Bullion 
U.S. Stock Futures Rise Ahead of Trump-Xi Summit, Middle East Risks Weigh 
Allegro Raises 2026 Outlook as International GMV Surges 
OpenAI Urges US-Led Global Standards for Frontier AI 
Wall Street Mixed as Treasury Yields Rise After Fed Hike 
Prysmian, Rio Tinto Supply Low-Carbon Cables for Amazon Ohio Data Center 
Add as a preferred source on Google
Moderna has assigned its new chief medical officer after recruiting a former Johnson & Johnson executive. It was reported that effective on July 6, Dr. Paul Burton will be joining the American pharmaceutical and biotechnology company based in Cambridge, Massachusetts.
As per Market Watch, Dr. Burton worked in Janssen Pharmaceuticals as its chief global medical affairs officer from March 2020, but he has been with Johnson & Johnson for 16 years and held various executive positions during his tenure.
Burton moves to Moderna
Dr. Paul Burton will be replacing Tal Zaks, who is said to be leaving Moderna after six years with the company. The incoming Moderna medical chief was also said to have previously worked as the vice president and head of cardiovascular and metabolic medical affairs in J&J.
He will be joining the biotech firm at the time when it is seeking approval from the government’s health regulators so that its COVID-19 vaccine could be used for adolescents too. Moderna’s chief executive officer, Stephane Bancel, said that testing results for the use of the vaccine in children will be available by fall. If the outcome is good, she said that it could help get a nod from the regulators and health safety boards.
“Paul’s extensive medical experience in the global pharmaceutical and biotech industry will be important to Moderna as we expand internationally and continue our journey as a commercial company,” CEO Bancel said in a press release. “As we work to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients, Paul’s expertise across multiple therapeutic areas and his proven track record leveraging data science and digital technologies to reimagine medical engagement will be invaluable.”
Moderna’s foray into COVID-19 vaccine production
Moderna’s name became popular after joining the list of pharmaceutical firms that develop and produce vaccines for COVID-19. Its label was often in the headlines since last year, and now it is considered as one of the leading suppliers of vaccines worldwide.
Moderna’s CEO believes that with Dr. Paul Burton’s expertise, the company will achieve more of its goals in the coming years. She said that she is really looking forward to working with the new medical chief as they could achieve many things together.
